AU2012225548B2 - Methods and compositions for treating depression using cyclobenzaprine - Google Patents

Methods and compositions for treating depression using cyclobenzaprine Download PDF

Info

Publication number
AU2012225548B2
AU2012225548B2 AU2012225548A AU2012225548A AU2012225548B2 AU 2012225548 B2 AU2012225548 B2 AU 2012225548B2 AU 2012225548 A AU2012225548 A AU 2012225548A AU 2012225548 A AU2012225548 A AU 2012225548A AU 2012225548 B2 AU2012225548 B2 AU 2012225548B2
Authority
AU
Australia
Prior art keywords
cyclobenzaprine
day
dose
depression
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012225548A
Other languages
English (en)
Other versions
AU2012225548A1 (en
Inventor
Seth Lederman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tonix Pharma Ltd Ireland
Original Assignee
Tonix Pharma Ltd Ireland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46796107&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2012225548(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tonix Pharma Ltd Ireland filed Critical Tonix Pharma Ltd Ireland
Publication of AU2012225548A1 publication Critical patent/AU2012225548A1/en
Application granted granted Critical
Publication of AU2012225548B2 publication Critical patent/AU2012225548B2/en
Priority to AU2016222412A priority Critical patent/AU2016222412B2/en
Priority to AU2018204633A priority patent/AU2018204633C1/en
Assigned to TONIX PHARMA HOLDINGS LIMITED reassignment TONIX PHARMA HOLDINGS LIMITED Request for Assignment Assignors: Tonix Pharmaceuticals, Inc.
Priority to AU2020203874A priority patent/AU2020203874B2/en
Assigned to TONIX PHARMA LIMITED reassignment TONIX PHARMA LIMITED Request for Assignment Assignors: TONIX PHARMA HOLDINGS LIMITED
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2012225548A 2011-03-07 2012-03-06 Methods and compositions for treating depression using cyclobenzaprine Active AU2012225548B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2016222412A AU2016222412B2 (en) 2011-03-07 2016-08-31 Methods and Compositions for Treating Depression Using Cyclobenzaprine
AU2018204633A AU2018204633C1 (en) 2011-03-07 2018-06-26 Methods and Compositions for Treating Depression Using Cyclobenzaprine
AU2020203874A AU2020203874B2 (en) 2011-03-07 2020-06-11 Methods and compositions for treating depression using cyclobenzaprine

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161449838P 2011-03-07 2011-03-07
US61/449,838 2011-03-07
PCT/US2012/027926 WO2012122193A1 (en) 2011-03-07 2012-03-06 Methods and compositions for treating depression using cyclobenzaprine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016222412A Division AU2016222412B2 (en) 2011-03-07 2016-08-31 Methods and Compositions for Treating Depression Using Cyclobenzaprine

Publications (2)

Publication Number Publication Date
AU2012225548A1 AU2012225548A1 (en) 2013-09-19
AU2012225548B2 true AU2012225548B2 (en) 2016-06-02

Family

ID=46796107

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2012225548A Active AU2012225548B2 (en) 2011-03-07 2012-03-06 Methods and compositions for treating depression using cyclobenzaprine
AU2016222412A Active AU2016222412B2 (en) 2011-03-07 2016-08-31 Methods and Compositions for Treating Depression Using Cyclobenzaprine
AU2018204633A Active AU2018204633C1 (en) 2011-03-07 2018-06-26 Methods and Compositions for Treating Depression Using Cyclobenzaprine
AU2020203874A Active AU2020203874B2 (en) 2011-03-07 2020-06-11 Methods and compositions for treating depression using cyclobenzaprine

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2016222412A Active AU2016222412B2 (en) 2011-03-07 2016-08-31 Methods and Compositions for Treating Depression Using Cyclobenzaprine
AU2018204633A Active AU2018204633C1 (en) 2011-03-07 2018-06-26 Methods and Compositions for Treating Depression Using Cyclobenzaprine
AU2020203874A Active AU2020203874B2 (en) 2011-03-07 2020-06-11 Methods and compositions for treating depression using cyclobenzaprine

Country Status (18)

Country Link
US (1) US11998516B2 (enExample)
EP (2) EP3682885A1 (enExample)
JP (2) JP2014507475A (enExample)
AU (4) AU2012225548B2 (enExample)
CA (1) CA2829200C (enExample)
CY (1) CY1122998T1 (enExample)
DK (1) DK2683245T4 (enExample)
ES (1) ES2773834T5 (enExample)
FI (1) FI2683245T4 (enExample)
HR (1) HRP20200142T4 (enExample)
HU (1) HUE048596T2 (enExample)
LT (1) LT2683245T (enExample)
PL (1) PL2683245T5 (enExample)
PT (1) PT2683245T (enExample)
RS (1) RS60240B2 (enExample)
SI (1) SI2683245T2 (enExample)
SM (1) SMT202000083T1 (enExample)
WO (1) WO2012122193A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011062614A1 (en) * 2009-11-20 2011-05-26 Tonix Pharmaceuticals, Inc. Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
NZ747040A (en) 2013-03-15 2020-02-28 Tonix Pharmaceuticals Inc Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
WO2015150948A1 (en) * 2014-03-29 2015-10-08 Wockhardt Limited Modified release solid oral pharmaceutical compositions of cyclobenzaprine or a salt thereof
SG11201701995PA (en) 2014-09-18 2017-04-27 Tonix Pharma Holdings Ltd Eutectic formulations of cyclobenzaprine hydrochloride
CN106890129A (zh) * 2015-12-18 2017-06-27 健乔信元医药生技股份有限公司 环苄普林之延释剂型
AU2018383098B2 (en) * 2017-12-11 2024-12-12 Tonix Pharma Limited Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395788B1 (en) * 1999-08-13 2002-05-28 Vela Pharmaceuticals, Inc. Methods and compositions for treating or preventing sleep disturbances and associated illnesses using very low doses of cyclobenzaprine
US20050096327A1 (en) * 2003-11-03 2005-05-05 Caprathe Bradley W. Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3882246A (en) 1971-05-21 1975-05-06 Merck & Co Inc Treatment of skeletal muscle disorders with cyclobenzaprine
US4968507A (en) 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
FR2635461B1 (fr) 1988-08-18 1992-01-17 Adir Utilisation de derives tricycliques pour l'obtention de medicaments destines au traitement du stress
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
SG47101A1 (en) 1992-07-31 1998-03-20 Us Bioscience Crystalline amifostine compositions and methods for the preparation and use of same
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
JP3746293B2 (ja) 1993-02-22 2006-02-15 アメリカン バイオサイエンス、インコーポレイテッド 生物製剤のインビボ送達の方法とそのための組成物
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US5354566A (en) 1993-06-02 1994-10-11 Kraft General Foods, Inc. Preparation of yeast-leavened dough crusts
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5834025A (en) 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
US6649186B1 (en) 1996-09-20 2003-11-18 Ethypharm Effervescent granules and methods for their preparation
US20030077227A1 (en) 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
WO1999018937A1 (en) 1997-10-16 1999-04-22 Merck & Co., Inc. New cyclobenzaprine composition
AU3885799A (en) 1998-05-14 1999-11-29 Alza Corporation Antidepressant therapy
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
BR0013122A (pt) 1999-08-13 2002-04-30 Vela Pharmaceuticals Inc Ciclobenzaprina para tratamento de distúrbio de ansiedade generalizado e composições de ciclobenzaprina
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
AU2001261744A1 (en) 2000-05-19 2001-12-03 Npd Llc Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements
DK1441708T3 (da) 2001-11-05 2009-07-06 Krele Pharmaceuticals Llc Sammensætninger og fremgangsmåder til forögelse af föjelighed med terapier ved anvendelse af aldehyddehydrogenase-inhibitorer og behandling af alkoholisme
US7105486B2 (en) 2002-02-22 2006-09-12 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds
US7659253B2 (en) 2002-02-22 2010-02-09 Shire Llc Abuse-resistant amphetamine prodrugs
US7700561B2 (en) 2002-02-22 2010-04-20 Shire Llc Abuse-resistant amphetamine prodrugs
US7038085B2 (en) 2002-10-25 2006-05-02 Collegium Pharmaceutical, Inc. Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof
EP1585548B1 (en) 2002-12-09 2018-06-27 Abraxis BioScience, LLC Compositions and methods of delivery of pharmacological agents
US8688385B2 (en) 2003-02-20 2014-04-01 Mayo Foundation For Medical Education And Research Methods for selecting initial doses of psychotropic medications based on a CYP2D6 genotype
US20050059656A1 (en) 2003-04-07 2005-03-17 Cornell Research Foundation, Inc. Compositions and methods for protecting against mitochondria component-mediated pathology
KR101159477B1 (ko) 2003-05-29 2012-07-02 샤이어 엘엘씨 남용 방지성 암페타민 화합물
US20050143350A1 (en) 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
EP1727520A2 (en) 2003-12-09 2006-12-06 Medcrystalforms, Llc Method of preparation of mixed phase co-crystals with active agents
KR20130116378A (ko) 2004-02-17 2013-10-23 트랜스셉트 파마슈티칼스, 인코포레이티드 구강 점막을 가로지르는 수면제 전달용 조성물 및 이의 사용 방법
TW200531680A (en) 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
US8216610B2 (en) 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
US20070196364A1 (en) 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
US7532935B2 (en) 2005-07-29 2009-05-12 Cyberonics, Inc. Selective neurostimulation for treating mood disorders
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US20090069267A1 (en) 2006-01-17 2009-03-12 Abrams Daniel J Central administration of stable formulations of therapeutic agents for cns conditions
US20080146672A1 (en) 2006-12-08 2008-06-19 Denton Marcia Marye Topical Eutectic Anesthetic Composition for Oral or Dermal Tissue
EP2514417A3 (en) 2007-05-07 2013-01-30 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
CA2690737A1 (en) 2007-06-22 2008-12-31 Merck Sharp & Dohme Corp. 6.5-pyrrolopiperidine tachykinin receptor antagonists
SG183069A1 (en) 2007-07-23 2012-08-30 Synosia Therapeutics Treatment of post-traumatic stress disorder
US20090060983A1 (en) 2007-08-30 2009-03-05 Bunick Frank J Method And Composition For Making An Orally Disintegrating Dosage Form
SI2200588T1 (sl) 2007-09-25 2019-08-30 Solubest Ltd. Sestavki, ki obsegajo lipofilne aktivne spojine, in postopek za njihovo pripravo
WO2009058950A2 (en) 2007-10-30 2009-05-07 Dr. Reddy's Laboratories Ltd. Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide
US20090148532A1 (en) 2007-12-06 2009-06-11 Venkatesh Gopi M Preparation of controlled release skeletal muscle relaxant dosage forms
JP5714910B2 (ja) 2008-01-09 2015-05-07 チャールストン ラボラトリーズ，インコーポレイテッド 薬学的組成物
CN102131483A (zh) 2008-02-08 2011-07-20 昌达生物科技公司 可控给药非聚合组合物
US9314469B2 (en) 2008-05-05 2016-04-19 Tonix Pharma Holdings Limited Method for treating neurocognitive dysfunction
JP5380909B2 (ja) 2008-05-30 2014-01-08 株式会社ブリヂストン 金型及び樹脂発泡成形品の成形方法
US20100266682A1 (en) 2008-12-10 2010-10-21 Nipun Davar Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same
US20100247586A1 (en) 2009-03-27 2010-09-30 Andreas Hugerth Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties
EP2233134A1 (en) 2009-03-27 2010-09-29 McNeil AB Multi-portion intra-oral dosage form with organoleptic properties
US8343533B2 (en) 2009-09-24 2013-01-01 Mcneil-Ppc, Inc. Manufacture of lozenge product with radiofrequency
WO2011062614A1 (en) 2009-11-20 2011-05-26 Tonix Pharmaceuticals, Inc. Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
US20130165511A1 (en) 2010-09-01 2013-06-27 TONIX Pharmaceuticals Holding Corp Treatment for cocaine addiction
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
ITMI20110558A1 (it) 2011-04-06 2012-10-07 Campiglio Consulting Srl Composizione farmaceutica contenente ciclobenzaprina adatta alla somministrazione endonasale
EP2861223B1 (en) 2012-06-15 2022-08-03 Tonix Pharma Holdings Limited Compositions and methods for transmucosal absorption
US9682948B2 (en) 2012-11-05 2017-06-20 Emory University 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto
NZ747040A (en) 2013-03-15 2020-02-28 Tonix Pharmaceuticals Inc Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
BR112017014375A2 (pt) 2014-07-18 2019-12-31 Medipath, Inc. composições e métodos para administração fisiológica usando canabidiol.
SG11201701995PA (en) 2014-09-18 2017-04-27 Tonix Pharma Holdings Ltd Eutectic formulations of cyclobenzaprine hydrochloride
AU2018383098B2 (en) 2017-12-11 2024-12-12 Tonix Pharma Limited Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
WO2023250036A1 (en) 2022-06-21 2023-12-28 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine treatment for post-acute sequelae of (sars)-cov-2 infection (pasc)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395788B1 (en) * 1999-08-13 2002-05-28 Vela Pharmaceuticals, Inc. Methods and compositions for treating or preventing sleep disturbances and associated illnesses using very low doses of cyclobenzaprine
US20050096327A1 (en) * 2003-11-03 2005-05-05 Caprathe Bradley W. Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GROF, P. et al., Activitas Nervosa Superior. 1965, vol. 7, no. 3, pages 288-289 *
VINAR, O. et al., Activitas Nervosa Superior. 1965, vol. 7, no. 3, page 290 *

Also Published As

Publication number Publication date
EP3682885A1 (en) 2020-07-22
ES2773834T5 (es) 2023-03-16
LT2683245T (lt) 2020-03-25
AU2018204633A1 (en) 2018-07-12
JP2014507475A (ja) 2014-03-27
AU2016222412B2 (en) 2018-03-29
ES2773834T3 (es) 2020-07-15
RS60240B1 (sr) 2020-06-30
US20120232159A1 (en) 2012-09-13
AU2018204633C1 (en) 2020-09-10
EP2683245B2 (en) 2022-12-07
SI2683245T1 (sl) 2020-07-31
JP2016053095A (ja) 2016-04-14
US11998516B2 (en) 2024-06-04
EP2683245A4 (en) 2014-08-27
WO2012122193A1 (en) 2012-09-13
SMT202000083T1 (it) 2020-05-08
HRP20200142T4 (hr) 2023-02-17
EP2683245B1 (en) 2019-12-25
CA2829200A1 (en) 2012-09-13
NZ614725A (en) 2016-07-29
DK2683245T3 (da) 2020-02-24
SI2683245T2 (sl) 2023-04-28
EP2683245A1 (en) 2014-01-15
PL2683245T5 (pl) 2023-03-20
AU2016222412A1 (en) 2016-09-22
CA2829200C (en) 2022-05-03
HUE048596T2 (hu) 2020-08-28
AU2020203874B2 (en) 2021-09-09
AU2018204633B2 (en) 2020-03-12
AU2020203874A1 (en) 2020-07-02
DK2683245T4 (da) 2023-01-09
CY1122998T1 (el) 2021-10-29
RS60240B2 (sr) 2023-05-31
AU2012225548A1 (en) 2013-09-19
NZ714294A (en) 2017-06-30
HRP20200142T1 (hr) 2020-06-26
PT2683245T (pt) 2020-02-21
PL2683245T3 (pl) 2020-10-05
FI2683245T4 (fi) 2023-01-13

Similar Documents

Publication Publication Date Title
AU2020203874B2 (en) Methods and compositions for treating depression using cyclobenzaprine
US10722478B2 (en) Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
DK2501234T3 (en) METHODS AND COMPOSITIONS FOR TREATING SYMPTOMS CONNECTED WITH POSTTRAUMATIC LOAD RESPONSE USING CYCLOBENZAPRINE
US20220016101A1 (en) Methods of treating depression, anxiety and sexual dysfunction using the compound pimavanserin
AU2018383098A1 (en) Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
CN116139130A (zh) 治疗戈谢病的方法
WO2022094230A1 (en) Compounds for treating psychosis or depression
NZ614725B2 (en) Methods and compositions for treating depression using cyclobenzaprine
NZ714294B2 (en) Methods And Compositions For Treating Depression Using Cyclobenzaprine
RU2781242C2 (ru) Способы лечения болезни гоше
Sequeira Central nervous system stimulants, drugs that suppress appetite, and drugs used in Alzheimer's disease
HK1176235A (en) Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine
HK1176235B (en) Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: TONIX PHARMA HOLDINGS LIMITED

Free format text: FORMER OWNER(S): TONIX PHARMACEUTICALS, INC.

PC Assignment registered

Owner name: TONIX PHARMA LIMITED

Free format text: FORMER OWNER(S): TONIX PHARMA HOLDINGS LIMITED